Dear Healthcare Professional Letter to physicians concerning supply of Cerezyme (imiglucerase) with revised temporary treatment recommendations
27.10.2009
The holder of the marketing authorisations for the medicinal products of Genezyme Corporation in Croatia, the company Medical Intertrade d.o.o., in cooperation with the Agency for Medicinal Products and Medical Devices sent a letter to prescribing physicians in connection with restricted supply of Cerezyme (imiglucerase). The letter contains new, revised temporary treatment recommendations in relation to those published in August 2009.
The revision established the minimum effective dosage of 15 U/kg every 2 weeks, as opposed to every 4 weeks and, among other, included the expanded list of specific examples in order to show which Gaucher disease patients are at a high risk of developing a life-threatening progression of the disease.
The full text of the letter can be found below: The letter to physicians concerning supply of Cerezyme (imiglucerase) with revised temporary treatment recommendations.
